Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

www.tevapharm.com

Latest From Teva Pharmaceutical Industries Ltd.

Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.

Launches Market Intelligence

Pfizer’s US Rituximab Launched At A 24% Discount

Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.

Launches Biosimilars

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Intellectual Property United States

Decade In Review: C-Suite Shifts At Family-Owned Indian Firms

Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.

India Commercial
See All

Company Information

UsernamePublicRestriction

Register